慢性阻塞性肺疾病与NLRP3炎症小体的研究进展

Research progress of NLRP3 inflammasome in chronic obstructive pulmonary disease

慢性阻塞性肺疾病(COPD)是临床上常见的呼吸系统疾病之一,目前是全球第三大死亡原因,严重威胁人类的生命健康。COPD确切的发生机制至今尚未完全阐明。核苷酸结合寡聚化结构域样受体家族含热蛋白结构域蛋白3(NLRP3)炎症小体通过多种机制调控肺部炎症的反应过程,从而参与COPD的发生和发展。本文进一步阐明炎症小体在COPD发病机制或干预中的作用,并提供了新的研究方向,NLRP3炎症小体及其调节的细胞因子或受体可能是肺部疾病和其他炎症介导的疾病的新的诊断或治疗靶点。

Chronic obstructive pulmonary disease(COPD),one of the common respiratory system diseases in clinical practice,is considered the third leading cause of death globally and poses a serious threat to human life and health.The precise mechanism of COPD is not completely understood so far.Through a variety of methods,NLRP3 inflammasome controls the response process of lung inflammation,contributing to the onset and progression of COPD.This article clarifies the role of inflammasome in the development or treatment of COPD and offers potential directions for future research.Inflammasomes and the cytokines or receptors regulated by inflammasomes could serve as new diagnostic or therapeutic targets for lung diseases and other inflammation-mediated disorders.